Basma Hussein S, Misch Craig M
Int J Oral Maxillofac Implants. 2021 Jan-Feb;36(1):122-25. doi: 10.11607/jomi.8461.
PURPOSE: The aim of this retrospective study was to determine if penicillin allergy and/or clindamycin therapy may contribute to a higher incidence of postsurgical infections after bone augmentation. MATERIALS AND METHODS: This retrospective study analyzed patients between 2014 and 2019 who received bone augmentation procedures (socket grafting [SG]; ridge augmentation [RA]) prior to placement of dental implants. All the grafting procedures were performed under preoperative and postoperative oral antibiotic coverage with either amoxicillin or clindamycin for patients who reported penicillin allergy. Infections associated with the bone augmentation procedures were recorded. RESULTS: In this study, 1,814 patients received 2,961 bone augmentation procedures (2,530 SG, 431 RA). In the 2,530 SG procedures, 270 (10.7%) were associated with a penicillin allergy. Infections occurred in 91 of the 2,530 SG sites (3.6%). However, the infection rate was 10.7% (29 SG sites) for clindamycin and only 2.7% (62 SG sites) for amoxicillin (P < .02). In the 431 RA procedures, 71 (16.5%) were associated with a penicillin allergy. Overall infections occurred in 31 of the 431 sites (7.2%). However, the infection rate was 22.5% (16 RA sites) for clindamycin and only 4.2% for amoxicillin (15 RA sites; P < .01). Penicillin-allergic patients taking clindamycin demonstrated a higher risk of infection with a risk ratio of 6.9 (95% CI) and 4.5 (95% CI) compared with nonallergic patients taking amoxicillin for RA and SG, respectively. CONCLUSION: Penicillin allergy and the use of clindamycin following SG and RA procedures was associated with a higher rate of infection and may be a risk factor for bone augmentation complications.
目的:本回顾性研究旨在确定青霉素过敏和/或克林霉素治疗是否可能导致骨增量术后感染发生率升高。 材料与方法:本回顾性研究分析了2014年至2019年间在植入牙种植体前接受骨增量手术(牙槽窝植骨[SG];牙槽嵴增高术[RA])的患者。对于报告有青霉素过敏的患者,所有植骨手术均在术前和术后使用阿莫西林或克林霉素进行口腔抗生素覆盖。记录与骨增量手术相关的感染情况。 结果:在本研究中,1814例患者接受了2961次骨增量手术(2530次SG,431次RA)。在2530次SG手术中,270例(10.7%)与青霉素过敏有关。2530个SG部位中有91个(3.6%)发生感染。然而,克林霉素治疗组的感染率为10.7%(29个SG部位),阿莫西林治疗组仅为2.7%(62个SG部位)(P <.02)。在431次RA手术中,71例(16.5%)与青霉素过敏有关。431个部位中共有31个(7.2%)发生总体感染。然而,克林霉素治疗组的感染率为22.5%(16个RA部位),阿莫西林治疗组仅为4.2%(15个RA部位;P <.01)。与服用阿莫西林的非过敏患者相比,服用克林霉素的青霉素过敏患者发生感染的风险更高,RA和SG的风险比分别为6.9(95%CI)和4.5(95%CI)。 结论:SG和RA手术后的青霉素过敏以及克林霉素的使用与较高的感染率相关,可能是骨增量并发症的一个危险因素。
Int J Oral Maxillofac Implants. 2021
J Stomatol Oral Maxillofac Surg. 2024-10
Int J Oral Maxillofac Implants. 2007
Int J Oral Maxillofac Implants. 2018
Clin Implant Dent Relat Res. 2022-6
J Dent Res. 2019-7-17
Antibiotics (Basel). 2021-10-9